Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Impact on the endemic HCV seroprevalence of reducing syringe sharing amongst high and low frequency syringe sharing IDUs. Projections are shown.

Published byJonas Burke Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 4 Impact on the endemic HCV seroprevalence of reducing syringe sharing amongst high and low frequency syringe sharing IDUs. Projections are shown."— Presentation transcript:

1 Figure 4 Impact on the endemic HCV seroprevalence of reducing syringe sharing amongst high and low frequency syringe sharing IDUs. Projections are shown for the best-fit models of class A, B and C, and the HCV seroprevalence is the average over all IDUs who have been injecting for eight years or less. Class A, B and C models have similar characteristics except that class A and C have a larger sub-group of higher frequency syringe sharers (37% and 47% of IDUs for A and C respectively) than class B (27% of IDUs), a higher proportion of infecteds resolve infection in class A and B (41–47%) than in class C (18%), and new injectors in class B have an elevated syringe sharing rate (3.3 times higher than other IDUs) but do not in class A or C From: Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study Int J Epidemiol. 2007;36(2): doi: /ije/dyl276 Int J Epidemiol | Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.

2 Figure 3 Impact on endemic HCV seroprevalence of reducing syringe sharing amongst all IDUs, or IDUs who have been injecting for >1 year. Projections are shown for the best-fit models of class A, B and C, and the HCV sero-prevalence is the average over all IDUs who have been injecting for ≤8 years. Class A, B and C models have similar characteristics except that class A and C have a larger sub-group of higher frequency syringe sharers (37 and 47% of IDUs for A and C respectively) than class B (27% of IDUs), a higher proportion of infecteds resolve infection in class A and B (41–47%) than in class C (18%), and new injectors in class B have an elevated syringe sharing rate (3.3 times higher than other IDUs) but do not in class A or C From: Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study Int J Epidemiol. 2007;36(2): doi: /ije/dyl276 Int J Epidemiol | Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.

3 Figure 2 Projected HCV seroprevalence for different syringe sharing rates among IDUs who have been injecting for different durations. Figure 2a is for the best fit of class A, and 2b is for class B. The projections for class C are similar to class A. Class A and B models have similar characteristics except that class A has a larger sub-group of higher frequency syringe sharers (37% of IDUs) than class B (27% of IDUs) and new injectors in class B have an elevated syringe sharing rate (3.3 times higher than other IDUs) but do not in class A From: Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study Int J Epidemiol. 2007;36(2): doi: /ije/dyl276 Int J Epidemiol | Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.

4 Appendix 1 Flow diagram for HCV transmission model
Appendix 1 Flow diagram for HCV transmission model. Arrows portray possible transformations of susceptible or infected IDUs, and the parameters next to these arrows are the rate of flow per capita between these states From: Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study Int J Epidemiol. 2007;36(2): doi: /ije/dyl276 Int J Epidemiol | Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.

5 Figure 1 Comparison of model fits to HCV seroprevalence data from London for 2002–03.<sup>19,</sup><sup>60</sup> The best-fit and the minimum and maximum bounds of the other 30 model fits are shown From: Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study Int J Epidemiol. 2007;36(2): doi: /ije/dyl276 Int J Epidemiol | Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2007; all rights reserved.

Download ppt "Figure 4 Impact on the endemic HCV seroprevalence of reducing syringe sharing amongst high and low frequency syringe sharing IDUs. Projections are shown."

Similar presentations

Presented by Cheri Booth, MPH MN Department of Health November 22, 2013.

Presented by Cheri Booth, MPH MN Department of Health November 22, 2013.
National Institute for Public Health and the Environment HIV, HCV, and HBV in injecting drug users in Europe Mirjam Kretzschmar Centre for Infectious Disease.

National Institute for Public Health and the Environment HIV, HCV, and HBV in injecting drug users in Europe Mirjam Kretzschmar Centre for Infectious Disease.
Epidemiology With Respect to the Dynamics of Infectious Diseases Huaizhi Chen.

Epidemiology With Respect to the Dynamics of Infectious Diseases Huaizhi Chen.
Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan by Abdul Rauf, Muhammad Shahid Nadeem, Akbar.

Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan by Abdul Rauf, Muhammad Shahid Nadeem, Akbar.
Figure 1 The spatial and temporal distribution of diarrhoea rates

Figure 1 The spatial and temporal distribution of diarrhoea rates
Figure 1: effects of the fire frequency and season treatments on cumulative mean fire intensity (mean intensity of all fires on a plot × number of fires/period.

Figure 1: effects of the fire frequency and season treatments on cumulative mean fire intensity (mean intensity of all fires on a plot × number of fires/period.
Figure 1. Flow diagram of participants recruited into the study.

Figure 1. Flow diagram of participants recruited into the study.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Am J Epidemiol. 2017;185(11): doi: /aje/kwx104

Am J Epidemiol. 2017;185(11): doi: /aje/kwx104
Figure 1. Period–cohort diagram.

Figure 1. Period–cohort diagram.
Figure 1 Timeline of the project.

Figure 1 Timeline of the project.
Figure 2. Number of cases required in a Mendelian randomization analysis with a binary outcome and a single instrumental variable for 80% power with a.

Figure 2. Number of cases required in a Mendelian randomization analysis with a binary outcome and a single instrumental variable for 80% power with a.
Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.

Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.
Fig 2. Sketch of the flow in the t-plane

Fig 2. Sketch of the flow in the t-plane
Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.

Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.
Figure 1 Infant mortality and gross national product (GNP) in selected Latin American countries and the United States, 2003 From: Health in Cuba Int J.

Figure 1 Infant mortality and gross national product (GNP) in selected Latin American countries and the United States, 2003 From: Health in Cuba Int J.
Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.

Figure 6 Case 6: (A) MRA showed occlusion of the left internal carotid artery. (B) MRI 4 days before cell injection and (C) 7 days after cell injection.
Figure 1. Flow diagram of Registrars’ participation in the study Intervention and analysis.#Pre-intervention number of registrars enrolled in.

Figure 1. Flow diagram of Registrars’ participation in the study Intervention and analysis.#Pre-intervention number of registrars enrolled in.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Fig. 1 Overview of model components to identify if hormonal pleiotropy constrains or facilitates phenotypic responses to selection. The environment imposes.

Fig. 1 Overview of model components to identify if hormonal pleiotropy constrains or facilitates phenotypic responses to selection. The environment imposes.

Similar presentations

Ads by Google